Literature DB >> 17873670

Measuring movement disorders in antipsychotic drug trials: the need to define a new standard.

Anton J M Loonen, Herman M van Praag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17873670     DOI： 10.1097/jcp.0b013e31814f1105

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  11 in total

1.  A Neural Signature of Parkinsonism in Patients With Schizophrenia Spectrum Disorders: A Multimodal MRI Study Using Parallel ICA.

Authors:  Robert C Wolf; Mahmoud Rashidi; Stefan Fritze; Katharina M Kubera; Georg Northoff; Fabio Sambataro; Vince D Calhoun; Lena S Geiger; Heike Tost; Dusan Hirjak
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

2.  Evaluation of health promotion programmes in severe mental illness: theory and practice.

Authors:  Fenneke M van Hasselt; Paul F M Krabbe; Maarten J Postma; Anton J M Loonen
Journal:  Int J Methods Psychiatr Res       Date:  2014-12-09       Impact factor: 4.035

3.  Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study.

Authors:  Manuel J Cuesta; Ana M Sánchez-Torres; Elena García de Jalón; Maria S Campos; Berta Ibáñez; Lucía Moreno-Izco; Víctor Peralta
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

4.  Harpagophytum Procumbens Ethyl Acetate Fraction Reduces Fluphenazine-Induced Vacuous Chewing Movements and Oxidative Stress in Rat Brain.

Authors:  Larissa Finger Schaffer; Catiuscia Molz de Freitas; Ana Paula Chiapinotto Ceretta; Luis Ricardo Peroza; Elizete de Moraes Reis; Bárbara Nunes Krum; Alcindo Busanello; Aline Augusti Boligon; Jéssie Haigert Sudati; Roselei Fachinetto; Caroline Wagner
Journal:  Neurochem Res       Date:  2016-01-06       Impact factor: 3.996

5.  Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia.

Authors:  Olga Yu Fedorenko; Anton J M Loonen; Florian Lang; Valentina A Toshchakova; Evgenia G Boyarko; Arkadiy V Semke; Nikolay A Bokhan; Nikolay V Govorin; Lyubomir I Aftanas; Svetlana A Ivanova
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-28       Impact factor: 5.176

6.  Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia.

Authors:  Ivan V Pozhidaev; Anastasiia S Boiko; Anton J M Loonen; Diana Z Paderina; Olga Yu Fedorenko; Gennadiy Tenin; Elena G Kornetova; Arkadiy V Semke; Nikolay A Bokhan; Bob Wilffert; Svetlana A Ivanova
Journal:  Appl Clin Genet       Date:  2020-04-22

7.  Neurobiological mechanisms associated with antipsychotic drug-induced dystonia.

Authors:  Anton Jm Loonen; Svetlana A Ivanova
Journal:  J Psychopharmacol       Date:  2020-09-09       Impact factor: 4.153

8.  NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.

Authors:  S A Ivanova; A J M Loonen; P Pechlivanoglou; M B Freidin; A F Y Al Hadithy; E V Rudikov; I A Zhukova; N V Govorin; V A Sorokina; O Y Fedorenko; V M Alifirova; A V Semke; J R B J Brouwers; B Wilffert
Journal:  Transl Psychiatry       Date:  2012-01-10       Impact factor: 6.222

9.  Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations.

Authors:  Svetlana A Ivanova; Anton Jm Loonen; P Roberto Bakker; Maxim B Freidin; Nienke J Ter Woerds; Asmar Fy Al Hadithy; Arkadiy V Semke; Olga Yu Fedorenko; Jacobus Rbj Brouwers; Nikolay A Bokhan; Jim van Os; Peter N van Harten; Bob Wilffert
Journal:  SAGE Open Med       Date:  2016-04-11

10.  5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia.

Authors:  Ivan V Pozhidaev; Diana Z Paderina; Olga Yu Fedorenko; Elena G Kornetova; Arkadiy V Semke; Anton J M Loonen; Nikolay A Bokhan; Bob Wilffert; Svetlana A Ivanova
Journal:  Front Mol Neurosci       Date:  2020-04-24       Impact factor: 5.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.